Clinical Trial: Study to Test a Marketed Drug in the Treatment of Menstrual Migraine

This study is not yet open for patient recruitment.

Sponsored by: Merck
Information provided by: Merck

Purpose

The purpose of this study is to test the effectiveness of a marketed drug in the treatment of a menstrual migraine attack.

Condition Treatment or Intervention Phase
Migraine
 Drug: Investigational Drug for the Treatment of Migraines
Phase II
Phase III

MedlinePlus related topics:  Migraine

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Female

Criteria

Inclusion Criteria:

  • Female patient at least 18 years old
  • Patient has menses approximately monthly
  • Patient has at least a 6 month history of migraine and at least a 6 month history of menstrual migraine

Exclusion Criteria:

  • Pregnant and/or nursing mother
  • Cardiovascular disease
  • Uncontrolled hypertension

Location and Contact Information

Please refer to this study by ClinicalTrials.gov identifier  NCT00111722

Toll Free Number      1-888-577-8839 

More Information

Study ID Numbers:  2005_025
Record last reviewed:  May 2005
Last Updated:  May 24, 2005
Record first received:  May 24, 2005
ClinicalTrials.gov Identifier:  NCT00111722
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-05-31

Resources




Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us